Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine.

Ashenagar, Mohammad Said; Matsumoto, Akiko; Sakai, Hironori; Tokiya, Mikiko; Hara, Megumi; Hirota, Yoshio

Ashenagar, Mohammad Said; Matsumoto, Akiko; Sakai, Hironori; Tokiya, Mikiko; Hara, Megumi; Hirota, Yoshio.

Afiliación

Ashenagar MS; Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Matsumoto A; Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Sakai H; Cellspect Co., Ltd., 2-4-23 Kitaiioka, Morioka 020-0857, Japan.
Tokiya M; Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Hara M; Department of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Hirota Y; Clinical Epidemiology Research Center, Medical Co., LTA(SOUSEIKAI), Higashi-ku, Fukuoka 813-0017, Japan.

Vaccines (Basel) ; 10(4)2022 Mar 22.

Article en En | MEDLINE | ID: mdl-35455236

Palabras clave

COVID-19; SARS-CoV-2; antibody; immunoassay tests; vaccination

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google